Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Shanghai HeartCare Medical Technology (HKSE:06609) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Shanghai HeartCare Medical Technology's EV-to-EBIT for today is
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Shanghai HeartCare Medical Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$97.2 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Shanghai HeartCare Medical Technology's EV-to-EBITDA for today is:
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Shanghai HeartCare Medical Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$128.2 Mil.
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Shanghai HeartCare Medical Technology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$448.9 Mil.
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Shanghai HeartCare Medical Technology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$169.7 Mil.
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Shanghai HeartCare Medical Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$154.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology Enterprise Value Related Terms
Shanghai HeartCare Medical Technology Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology Enterprise Value Chart
HKSE:06609 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai HeartCare Medical Technology Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Shanghai HeartCare Medical Technology's Enterprise Value falls into.
Shanghai HeartCare Medical Technology Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$1,064.9 Mil mean?
Shanghai HeartCare Medical Technology (HKSE:06609) has a Enterprise Value of HK$1,064.9 Mil as of Aug. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shanghai HeartCare Medical Technology and its competitors.
Is Shanghai HeartCare Medical Technology's Enterprise Value too high?
Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's Enterprise Value compare to ABT and SYK?
Shanghai HeartCare Medical Technology's Enterprise Value of HK$1,064.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shanghai HeartCare Medical Technology and its competitors. Shanghai HeartCare Medical Technology's current Enterprise Value is HK$1,064.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current Enterprise Value is HK$1,064.9 Mil. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current Enterprise Value is HK$1,064.9 Mil as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
Enterprise Value: HK$1,064.9 Mil
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
